You just read:

Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3½-Year Follow-Up Data of IMBRUVICA® (ibrutinib)

News provided by

Janssen Biotech, Inc.

Dec 09, 2017, 11:05 ET